238 related articles for article (PubMed ID: 37406255)
1. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
3. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
4. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.
Atrash S; Ali SA; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):21-34. PubMed ID: 33046423
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
8. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
Palomba ML; Qualls D; Monette S; Sethi S; Dogan A; Roshal M; Senechal B; Wang X; Rivière I; Sadelain M; Brentjens RJ; Park JH; Smith EL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173030
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
Talleur AC; Myers R; Annesley C; Shalabi H
Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
[TBL] [Abstract][Full Text] [Related]
10. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.
Kampouri E; Little JS; Rejeski K; Manuel O; Hammond SP; Hill JA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14157. PubMed ID: 37787373
[TBL] [Abstract][Full Text] [Related]
11. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
12. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
14. New targets for CAR T therapy in hematologic malignancies.
Savani M; Oluwole O; Dholaria B
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
[TBL] [Abstract][Full Text] [Related]
15. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
16. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
18. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
19. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
Mucha SR; Rajendram P
Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
[TBL] [Abstract][Full Text] [Related]
20. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]